5 billion acquisition of Belgium-based Solvay Pharmaceuticals read.

Abbott Completes Acquisition of Solvay Pharmaceuticals Abbott today announced that it has completed its EUR 4.5 billion acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a big and complementary portfolio of pharmaceutical products and expanding Abbott’s existence in important global emerging markets. Based on the timing of the close, Abbott expects the acquisition to add around $2 read .9 billion to Abbott’s 2010 total reported sales, almost all outside the U.S., and add around $500 million to Abbott’s annual pharmaceutical R&D investment. The acquisition of Solvay Pharmaceuticals is a key part of Abbott’s technique to bolster our presence in key marketplaces and deliver sustainable, industry-leading growth, said Miles D.